New Hope for Non-Hodgkin’s Lymphoma Patients: Verismo’s SynKIR-310 Enters Clinical Trial Phase

Verismo Therapeutics, a U.S. subsidiary of HLB developing next-generation CAR-T cell therapies, announced on the 5th that it has submitted a Phase 1 clinical trial plan (IND) to the U.S. Food and Drug Administration (FDA) for SynKIR-310, a treatment for recurrent/refractory non-Hodgkin’s lymphoma.

The clinical trial will target patients with various types of lymphoma, including diffuse large B-cell lymphoma (DLBCL), a type of blood cancer, and recurrent, refractory B-cell non-Hodgkin’s lymphoma (NHL).

While currently approved CAR-T therapies have a high response rate in blood cancers, over time, relapse occurs in 40-50% of patients, highlighting a clear limitation. Moreover, the treatment options are extremely limited for patients who relapse after receiving CAR-T therapy, as traditional CAR-T treatments no longer show therapeutic effects.

According to Verismo, co-founders and University of Pennsylvania (UPenn) professors Dr. Donald Siegel and Dr. Michael Milone have successfully developed a unique CD19 binder (DS191) that targets CD19, a key target antigen of B-cell-derived cancer. Combining this with Verismo’s multi-chain KIR-CAR platform, it is expected to remain activated longer than existing CAR-T cells and effectively suppress cancer recurrence while demonstrating effective anti-cancer effects.

Dr. Laura Johnson of Verismo, who planned this clinical trial, said, “SynKIR-310 can provide a new treatment option for patients who are difficult to treat with existing CAR-T therapies, especially those with recurrent, refractory B-cell non-Hodgkin’s lymphoma. We expect it to effectively prevent early cancer recurrence by enhancing the resistance of aggressive lymphoma patients and the anti-cancer function of T-cells.”